IHM
ESPR

Iguana Healthcare Management’s Esperion Therapeutics ESPR Stock Holding History

Iguana Healthcare Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$3.62M Buy
+50,000
New +$3.67M 2.38% 11
2016
Q4 		– Sell
-100,000
Closed -$1.39M – 68
2016
Q3 		$1.39M Buy
+100,000
New +$1.13M 0.25% 74

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Iguana Healthcare Management's ESPR Position: Q1 2018 in Review

Iguana Healthcare Management reduced its Esperion Therapeutics (ESPR) stake by 39% in Q1 2018, selling an estimated $4.77M and leaving 100,000 shares worth $7.23M. The position accounts for 4.76% of the portfolio, ranked #2.

Iguana Healthcare Management first reported a position in ESPR in Q4 2013 and has held it in 14 quarters since. The position peaked at $18.5M in Q1 2015. 187 funds tracked by Wall St. Rank hold ESPR as of Q1 2018.

  • Iguana Healthcare Management held 100,000 shares of Esperion Therapeutics worth $7.23M as of Q1 2018.
  • Iguana Healthcare Management sold 65,000 Esperion Therapeutics shares in Q1 2018, an estimated $4.77M.
  • Esperion Therapeutics made up 4.76% of Iguana Healthcare Management's portfolio in Q1 2018, its #2 holding.
  • Iguana Healthcare Management first reported a position in Esperion Therapeutics in Q4 2013 and has held it in 14 quarters since.
  • Iguana Healthcare Management's Esperion Therapeutics position peaked at $18.5M in Q1 2015.
  • 187 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2018.

Based on Iguana Healthcare Management's 13F filing for Q1 2018, filed 15 May 2018.